Daliresp (Cardinal Health)


Welcome to the PulseAid listing for the Daliresp drug offered from Cardinal Health. This Phosphodiesterase 4 Inhibitor [EPC],Phosphodiesterase 4 Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Cardinal Health
NON-PROPRIETARY NAME: roflumilast
SUBSTANCE NAME: ROFLUMILAST
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Phosphodiesterase 4 Inhibitor [EPC],Phosphodiesterase 4 Inhibitors [MoA]
ROUTE: ORAL
DOSAGE FORM: TABLET
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2011-02-28
END MARKETING DATE: 0000-00-00


Daliresp HUMAN PRESCRIPTION DRUG Details:

Item DescriptionDaliresp from Cardinal Health
LABELER NAME: Cardinal Health
DEA SCHEDULE:
ACTIVE STRENGTH: 500(ug/1)
START MARKETING DATE: 2011-02-28
END MARKETING DATE: 0000-00-00
PRODUCT ID: 55154-4625_dcd42444-048d-47dc-9a6e-2a94ab44b4f2
PRODUCT NDC: 55154-4625
APPLICATION NUMBER: NDA022522

Other ROFLUMILAST Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
AstraZeneca Pharmaceuticals LPDaliresp
Cardinal HealthDaliresp
Forest Laboratories, Inc.Daliresp